Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
about
EGFR/Met association regulates EGFR TKI resistance in breast cancerTargeting the hepatocyte growth factor-cMET axis in cancer therapyThe MET axis as a therapeutic target.An overview of the c-MET signaling pathwayH19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expressionDetection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reactionThe clinical and functional significance of c-Met in breast cancer: a reviewReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersNormal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factorc-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinomaConstitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer modelsNK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivoDisassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.Weight Loss Reversed Obesity-Induced HGF/c-Met Pathway and Basal-Like Breast Cancer ProgressionIn vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor.Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.The Met oncogene and basal-like breast cancer: another culprit to watch out for?GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer.Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.The role of the c-Met pathway in lung cancer and the potential for targeted therapy.HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancerTAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.Differential mitogenic effects of single chain hepatocyte growth factor (HGF)/scatter factor and HGF/NK1 following cleavage by factor Xa.Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells.Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancerAptamers Binding to c-Met Inhibiting Tumor Cell MigrationDiverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factorGDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase.Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts.High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers.cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancerThe mutationally activated Met receptor mediates motility and metastasis.DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma.Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer.Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells.Serum hepatocyte growth factor and cancer mortality in an apparently healthy Japanese population.Met and its ligand HGF are associated with clinical outcome in breast cancer.Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situGrowth factor signaling pathways as targets for prevention of epithelial carcinogenesis.
P2860
Q24338635-F65F89B9-9E3E-424E-9514-625B9B205B01Q24606259-BECBA116-20BE-4557-8DCE-FA3CF4810B59Q24609682-5EF1ACEE-B9E3-464C-A874-5EE5A057C57FQ24633986-F862E2D8-A1F5-4323-8EF7-B86B7DFA16B9Q24682023-08EED7B9-542F-4C6C-B12A-448339AE096DQ24803522-ECDFFA9E-BFCB-4983-BFDC-BF93A7307853Q28081415-2E56477A-947B-4427-8882-7B151EA6710CQ28082793-A43B7A5B-3C8B-4C65-A376-124A69F84D52Q28345285-02E40AC9-41F5-4EBC-B495-2E9C3E27D2D5Q28362076-5DE73C20-AD60-4D75-B913-D55A54F21846Q31062741-0013414D-C980-449C-8A05-61C818D51869Q33645135-12319DCC-A89D-4248-95FC-92F88AB40FEDQ33772210-6C116D6E-94DD-4CF9-A08A-0DE899433622Q33786959-30C307BA-C69B-4B3A-90AD-7DA9E374477EQ33859809-0191137C-7736-43C3-8FB2-5452D7C385DBQ34064613-6C8F6A9A-1923-4E8F-BEBF-F3C93F13E4D3Q34085432-2BAADC7D-7C36-44AE-9D46-44018EA2F6B6Q34173500-57357E01-08EB-4074-9656-265C10D6B3CFQ35072671-861F29F7-5405-48B0-8E6B-2EFFC1A7C626Q35102980-F30C112E-6DF1-4FDD-9155-9496C27F910DQ35146937-E9BB00F5-36EE-408C-B2D2-968709094F72Q35174872-A3826A8F-6DBF-4320-A2F3-480EBA354954Q35525917-746720B8-5511-448C-B61B-FDB16AA7EC79Q35677691-5A54BA92-CCF3-4655-8544-81CFAA7FFF09Q35829375-9687D3E4-6DB9-4442-8E02-D15437EE4241Q35829554-80967D7A-88D7-498B-9289-EBE02317C3F9Q35866739-A52FB78A-9EC7-419B-A7B9-A3B19E1C789AQ35961109-16713FFD-548F-4E3D-9C3F-54D9411FDA66Q36323379-88FDE282-6D84-413B-BBC9-599E8FAB105FQ36619559-2DC5ED6C-3630-4D72-A594-F63A38CEBCACQ36619905-7F0BB221-5AFC-4919-8F42-DFADB9B809BBQ36703854-91F118E0-0655-42F3-B8F4-8F52A56BE1F6Q36735738-4DC3082F-87AC-4685-8BF2-0E9FB2B58C2FQ36868117-F4BEEAE2-1ED4-45B2-8509-5F7FC7F430CAQ37111358-ED5E15E2-20BC-46DB-8391-F12915450479Q37228635-1B73D1DE-271F-412C-8660-08DF6DC60D68Q37234448-B8780C23-506F-476E-A2CA-DF4D8E00615AQ37392930-EBD329D4-63D2-41B3-92B1-45B36CD9C059Q37460978-D647B12B-4B68-4CE3-B74B-5AC4E74D6700Q37774602-E55704F7-FA8E-4A42-953B-9BF75208F609
P2860
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
@ast
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
@en
type
label
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
@ast
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
@en
prefLabel
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
@ast
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
@en
P2093
P2860
P1476
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
@en
P2093
P2860
P304
P407
P577
1996-01-01T00:00:00Z